Yanbo Pan

Forskningsbeskrivning

Mass spectrometry (MS)-based quantitative proteomics and its clinical applications

Proteomics is a field aiming for systems-level analysis of proteins in an organism or system. This generates new knowledge in biology to discover clinical biomarkers and drug targets. With cutting-edge MS-based quantitative proteomics (label-based and label-free), we can decipher the molecular phenotypes of different patients at the protein level. The ultimate aim is to develop differential tests to be used as clinical evaluation tools.

Temporal spatial proteomics to improve understanding of protein level signaling in anti-cancer treatment

Protein localization and re-localization in the different compartments of cells is an essential control mechanism for cellular functions as well as intercellular communication in multicellular organisms. we are developing methods for protein subcellular localization analysis (Molecular Cell 2019, Nature Reviews Methods Primers 2021, Nature Protocols 2022) and trying to understand how proteins shuttle between different subcellular compartments in response to drug treatments and ultimately how this affects the drug sensitivity in cancer treatment.

Functional proteomics and proteogenomics for personalized medicine

Proteogenomics links DNA, RNA, and protein measurements into a central-dogma perspective and has the potential to improve our understanding of cancer biology. By using robust quantitative proteomics and proteogenomics to generate information about protein activity, protein complex formation, and genetic aberrant results in cancer cells and clinical tumors (Oncogene 2019, Nature Cancer 2021). we are generating new information to suggest novel biomarkers and drug combinations for improved cancer therapy.